Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma: in Vivo Purging With Rituximab Versus Ex-Vivo Purging With Clinamacs CD34+ Cell Enrichment Device

Trial Profile

Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma: in Vivo Purging With Rituximab Versus Ex-Vivo Purging With Clinamacs CD34+ Cell Enrichment Device

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2010

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Etoposide; Filgrastim
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Mar 2010 Actual patient number (37) added as reported by ClinicalTrials.gov record.
    • 16 Mar 2010 Actual end date (1 Mar 2009) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top